Grant: Engage Grants Program
University of Ontario Institute of Technology
$25,000.00
Synthesis and Evaluation of Chemically-Modified siRNAs that Target bcl-2
FY 2013-14
Summary
Short Interfering RNAs (siRNAs) represents a class of molecules that have promise for downstreambiotechnology applications. DLVR Therapeutics, is a company that delivers siRNAs to specific tissues byusing an HDL-mimetic phospholipid-based nanoparticle called HPPS (HDL-like Peptide-PhospholipidScaffold). However, siRNAs have persistent problems within the biological milieu due unoptimized chemicalarchitecture. For example, siRNAs are susceptible to degradation, off-target effects and may inadvertentlyactivate the immune system. The proposal outlined will address the aforementioned issues with the goal ofattaining increased efficacy of the siRNA that targets the bcl-2 gene through novel chemical siRNA synthesis.The work described will foster a new collaboration between the University of Ontario Institute of Technologyand the biotechnology sector. Furthermore, the knowledge gained through development ofchemically-modified siRNAs will offer new promise for biotechnology and the life sciences.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
451441-2013
Name nom
Desaulniers, JeanPaul
Department département
Head Office
Organization id
19222
Institution établissement
University of Ontario Institute of Technology
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthesis and Evaluation of Chemically-Modified siRNAs that Target bcl-2
Keyword
NSERC
Application summary
Short Interfering RNAs (siRNAs) represents a class of molecules that have promise for downstreambiotechnology applications. DLVR Therapeutics, is a company that delivers siRNAs to specific tissues byusing an HDL-mimetic phospholipid-based nanoparticle called HPPS (HDL-like Peptide-PhospholipidScaffold). However, siRNAs have persistent problems within the biological milieu due unoptimized chemicalarchitecture. For example, siRNAs are susceptible to degradation, off-target effects and may inadvertentlyactivate the immune system. The proposal outlined will address the aforementioned issues with the goal ofattaining increased efficacy of the siRNA that targets the bcl-2 gene through novel chemical siRNA synthesis.The work described will foster a new collaboration between the University of Ontario Institute of Technologyand the biotechnology sector. Furthermore, the knowledge gained through development ofchemically-modified siRNAs will offer new promise for biotechnology and the life sciences.
